# A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression

> **NCT05189197** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fudan University** · enrollment: 41 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma(DLBCL)

## Interventions

- **DRUG:** Zanubrutinib + R-CHOP

## Key facts

- **NCT ID:** NCT05189197
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-18
- **Primary completion:** 2025-01
- **Final completion:** 2026-01
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2024-05-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05189197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05189197, "A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05189197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*